Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions

Lancet Oncol. 2017 Dec;18(12):1568-1569. doi: 10.1016/S1470-2045(17)30844-6. Epub 2017 Nov 13.

Authors

Mariana Chavez-MacGregor¹, Elizabeth A Mittendorf²

Affiliations

¹ Departments of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA; Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
² Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. Electronic address: eamitten@mdanderson.org.

PMID: 29146400
DOI: 10.1016/S1470-2045(17)30844-6

No abstract available

Publication types

Comment

MeSH terms

Breast Neoplasms*
Chemotherapy, Adjuvant
Humans
Receptor, ErbB-2
Trastuzumab*

Substances

Receptor, ErbB-2
Trastuzumab